ENTAENANTA PHARMACEUTICALS INC
Pharmaceutical Preparations
- Revenue
- $65M
- 3.4% YoY
- Operating margin
- -130.7%
- 27% YoY
- EBITDA
- −$81M
- 32% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired28% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $97M | $86M | $79M | $68M | $65M | 3.4% |
| Operating income | −$110M | −$124M | −$137M | −$122M | −$85M | 30% |
| Net income | −$79M | −$122M | −$134M | −$116M | −$82M | 29% |
| Operating cash flow | −$70M | −$85M | −$103M | −$79M | −$19M | 76% |
| Capex | $750K | $2M | $9M | $18M | $13M | 28% |
| Stock-based comp | $21M | $27M | $28M | $27M | $19M | 31% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.